AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 30747313 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation
Number of subjects: 250
Study 30747313 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral intervention
Number of subjects: 250
Study 30747311 — intervention group
Group type: EXPERIMENTAL
Intervention: Detoxified alcohol-dependent patients
Number of subjects: 39
Study 30747311 — intervention group
Group type: COMPARATOR
Intervention: Matched healthy controls
Number of subjects: 39
Study 30747374 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimally invasive resections
Number of subjects: 1546
Study 30747374 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall morbidity
Number of subjects: 1546
Study 30747374 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall mortality
Number of subjects: 1546
Study 30747374 — intervention group
Group type: EXPERIMENTAL
Intervention: Readmission
Number of subjects: 1546
Study 30747374 — intervention group
Group type: EXPERIMENTAL
Intervention: Reoperation
Number of subjects: 1546
Study 30747374 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-operative length of stay (LOS)
Number of subjects: 1546
Study 30747487 — intervention group
Group type: EXPERIMENTAL
Intervention: Endothelial microparticles (EMP) in SSc-PAH patients
Number of subjects: 30
Study 30747487 — intervention group
Group type: COMPARATOR
Intervention: Endothelial microparticles (EMP) in SSc patients
Number of subjects: 30
Study 30747487 — intervention group
Group type: EXPERIMENTAL
Intervention: Endothelial microparticles (EMP) in limited SSc patients
Number of subjects: 30
Study 30747487 — intervention group
Group type: EXPERIMENTAL
Intervention: Microparticles (MP) from SSc patients
Number of subjects: 30
Study 30747487 — intervention group
Group type: COMPARATOR
Intervention: Microparticles (MP) from healthy controls
Number of subjects: 30
Study 30747550 — intervention group
Group type: EXPERIMENTAL
Intervention: Scalp Itch Numeric Rating Scale
Number of subjects: 0
Study 30747719 — intervention group
Group type: EXPERIMENTAL
Intervention: Incentives for adherence to antidepressant medications in the first 6 weeks of treatment (Project 1: ADAPT)
Number of subjects: 0
Study 30747719 — intervention group
Group type: EXPERIMENTAL
Intervention: Normative pressure and social status to increase data collection among community mental health workers (Project 2: ASSISTS)
Number of subjects: 0
Study 30747719 — intervention group
Group type: EXPERIMENTAL
Intervention: Participatory design for organizational-level implementation strategies (Project 3: MOTIVATE)
Number of subjects: 0
Study 30753254 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorthalidone
Number of subjects: 236
Study 30753254 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 236
Study 30753254 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol/Candesartan
Number of subjects: 236
Study 30753274 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel and trastuzumab
Number of subjects: 406
Study 30753496 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative B-type natriuretic peptide (BNP) measurement
Number of subjects: 27
Study 30753496 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative BNP measurement on day 1 and day 2
Number of subjects: 27
Study 30753496 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-min walk test and Medical Research Council dyspnoea scale
Number of subjects: 27
Study 30753496 — intervention group
Group type: EXPERIMENTAL
Intervention: BNP levels at all perioperative time points
Number of subjects: 27
Study 30753549 — intervention group
Group type: EXPERIMENTAL
Intervention: Tryptophan intake ranging from 0.5 to 9.75 mg.kg-1.d-1
Number of subjects: 7
Study 30753549 — intervention group
Group type: COMPARATOR
Intervention: Current recommended EAR and RDA for healthy growing children
Number of subjects: 7
Study 30753611 — intervention group
Group type: EXPERIMENTAL
Intervention: IMA950/poly-ICLC vaccine
Number of subjects: 19
Study 30753685 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary supplements (DS)
Number of subjects: 0
Study 30753761 — intervention group
Group type: EXPERIMENTAL
Intervention: Cannabinoids
Number of subjects: 251
Study 30753761 — intervention group
Group type: EXPERIMENTAL
Intervention: Synthetic cannabinoids
Number of subjects: 251
Study 30755071 — intervention group
Group type: EXPERIMENTAL
Intervention: β-blockers
Number of subjects: 2932
Study 30755071 — intervention group
Group type: COMPARATOR
Intervention: No β-blockers
Number of subjects: 2932
Study 30755109 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone-delivered, nurse-led symptom management intervention
Number of subjects: 25
Study 30755362 — intervention group
Group type: EXPERIMENTAL
Intervention: VSR
Number of subjects: 146
Study 30755362 — intervention group
Group type: COMPARATOR
Intervention: FWR
Number of subjects: 146
Study 30755362 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous repair at 1-2 weeks following AMI
Number of subjects: 146
Study 30755445 — intervention group
Group type: EXPERIMENTAL
Intervention: AGuIX nanoparticles combined with WBRT (30 Gy, 10 fractions of 3 Gy)
Number of subjects: 15
Study 30755498 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressurised intraperitoneal aerosol chemotherapy (PIPAC)
Number of subjects: 35
Study 30755498 — intervention group
Group type: COMPARATOR
Intervention: Negative control group (benign PLF specimens and inflammatory ascites)
Number of subjects: 35
Study 30755498 — intervention group
Group type: EXPERIMENTAL
Intervention: PIPAC treatment response
Number of subjects: 35
Study 30755907 — intervention group
Group type: EXPERIMENTAL
Intervention: Obinutuzumab (initial test dose)
Number of subjects: 1
Study 30756297 — intervention group
Group type: EXPERIMENTAL
Intervention: 100% pasteurized watermelon juice (360 ml)
Number of subjects: 8
Study 30756308 — intervention group
Group type: EXPERIMENTAL
Intervention: BI 853520 200 mg once daily (QD)
Number of subjects: 96
Study 30756308 — intervention group
Group type: EXPERIMENTAL
Intervention: BI 853520 200 mg QD
Number of subjects: 96
Study 30756321 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported habitual snoring (snorers group, n=787)
Number of subjects: 4495
Study 30756321 — intervention group
Group type: COMPARATOR
Intervention: Nonsnoring (nonsnorers group, n=3708)
Number of subjects: 4495
Study 30756337 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal bimanual compression of a self-inflating resuscitation bag
Number of subjects: 35
Study 30756337 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximal bimanual compression of a self-inflating resuscitation bag
Number of subjects: 35
Study 30758276 — intervention group
Group type: EXPERIMENTAL
Intervention: High-priority stroke dispatch code
Number of subjects: 625
Study 30758276 — intervention group
Group type: EXPERIMENTAL
Intervention: Bystander caller
Number of subjects: 625
Study 30758276 — intervention group
Group type: EXPERIMENTAL
Intervention: Confusion
Number of subjects: 625
Study 30758276 — intervention group
Group type: EXPERIMENTAL
Intervention: Fall at onset
Number of subjects: 625
Study 30758276 — intervention group
Group type: EXPERIMENTAL
Intervention: Older age
Number of subjects: 625
Study 30758276 — intervention group
Group type: EXPERIMENTAL
Intervention: Call recordings analysis
Number of subjects: 625
Study 30758293 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavior change technique-based smartphone game
Number of subjects: 36
Study 30758293 — intervention group
Group type: COMPARATOR
Intervention: One-time lifestyle counseling
Number of subjects: 36
Study 30758297 — intervention group
Group type: EXPERIMENTAL
Intervention: Near-real-time financial incentives for weight loss and/or dietary self-monitoring
Number of subjects: 96
Study 30758297 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile health tools (mobile phone apps, cellular body weight scales, text messaging)
Number of subjects: 96
Study 30758653 — intervention group
Group type: EXPERIMENTAL
Intervention: ab interno subconjunctival gelatin implant (phaco + implant)
Number of subjects: 202
Study 30758653 — intervention group
Group type: EXPERIMENTAL
Intervention: ab interno subconjunctival gelatin implant (implant alone)
Number of subjects: 202
Study 30758786 — intervention group
Group type: EXPERIMENTAL
Intervention: DAAs for 3 months
Number of subjects: 160
Study 30758786 — intervention group
Group type: COMPARATOR
Intervention: Control group (no DAAs)
Number of subjects: 160
Study 30758975 — intervention group
Group type: EXPERIMENTAL
Intervention: Arterial Vascular Pruning
Number of subjects: 0
Study 30758975 — intervention group
Group type: EXPERIMENTAL
Intervention: Right Ventricular Size
Number of subjects: 0
Study 30758975 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical Outcomes
Number of subjects: 0
Study 30759059 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 30760013 — intervention group
Group type: EXPERIMENTAL
Intervention: Active psoriasis patients
Number of subjects: 20
Study 30760105 — intervention group
Group type: EXPERIMENTAL
Intervention: Suppression of tumorigenicity-2
Number of subjects: 263
Study 30760105 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth differentiation factor-15
Number of subjects: 263
Study 30760105 — intervention group
Group type: EXPERIMENTAL
Intervention: Matrix metalloproteinase-2
Number of subjects: 263
Study 30760105 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeatedly measured biomarkers (suppression of tumorigenicity-2, galectin-3, galectin-4, growth differentiation factor-15, matrix metalloproteinase-2 and 9, tissue inhibitor metalloproteinase-4, perlecan, cathepsin-D, cystatin-B)
Number of subjects: 263
Study 30760105 — intervention group
Group type: EXPERIMENTAL
Intervention: Biomarker trajectories
Number of subjects: 263
Study 30760224 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent auscultation augmented with fetal scalp stimulation (N=267)
Number of subjects: 568
Study 30760224 — intervention group
Group type: COMPARATOR
Intervention: Intermittent auscultation alone (N=251)
Number of subjects: 568
Study 30760246 — intervention group
Group type: EXPERIMENTAL
Intervention: Objective physical activity measured by GT3X+ ActiGraph
Number of subjects: 602
Study 30760246 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary measures based on a 24-h food recall
Number of subjects: 602
Study 30760246 — intervention group
Group type: EXPERIMENTAL
Intervention: Biomarkers measuring cancer risk (insulin resistance, inflammation, oxidative stress)
Number of subjects: 602
Study 30760246 — intervention group
Group type: EXPERIMENTAL
Intervention: Environmental exposure calculated using static and dynamic measures
Number of subjects: 602
Study 30760295 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate short-term hyperventilation (HV)
Number of subjects: 11
Study 30760395 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral Activation (BA) approach to parent training
Number of subjects: 11
Study 30760451 — intervention group
Group type: EXPERIMENTAL
Intervention: Thalidomide-cyclophosphamide-prednisone (TCP) regimen
Number of subjects: 25
Study 30760466 — intervention group
Group type: EXPERIMENTAL
Intervention: Pracinostat 60 mg/d, 3 d/wk for 3 consecutive weeks plus azacitidine 75 mg/m²
Number of subjects: 0
Study 30761059 — intervention group
Group type: EXPERIMENTAL
Intervention: Adapted cognitive behavioral treatment
Number of subjects: 0
Study 30761059 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 0
Study 30761066 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual reality (VR) systems with different kinds of interaction devices
Number of subjects: 0
Study 30761076 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Number of subjects: 0
Study 30761076 — intervention group
Group type: COMPARATOR
Intervention: Ticlopidine
Number of subjects: 0
Study 30761078 — intervention group
Group type: EXPERIMENTAL
Intervention: Smart Device System (SDS) for multi-modal high-resolution acceleration measurement
Number of subjects: 0
Study 30761078 — intervention group
Group type: EXPERIMENTAL
Intervention: Smart Device System (SDS) including smartphone-based questionnaires, two smartwatches, and tablet-based Archimedean spirals drawing
Number of subjects: 0
Study 30761278 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing PEEP (Positive End-Expiratory Pressure)
Number of subjects: 0
Study 30761278 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 30761601 — intervention group
Group type: EXPERIMENTAL
Intervention: fMRI version of the Suicide Implicit Association Task (S-IAT)
Number of subjects: 28
Study 30762084 — intervention group
Group type: EXPERIMENTAL
Intervention: Gefitinib exposure at the time of ILD occurrence
Number of subjects: 336
Study 30762084 — intervention group
Group type: EXPERIMENTAL
Intervention: Gefitinib exposure
Number of subjects: 336
Study 30762508 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin (20 mg once daily)
Number of subjects: 150
Study 30762508 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150
Study 30762582 — intervention group
Group type: COMPARATOR
Intervention: Fitbit Charge alone
Number of subjects: 91
Study 30762582 — intervention group
Group type: EXPERIMENTAL
Intervention: Fitbit Charge with MI and habit education
Number of subjects: 91
Study 30762582 — intervention group
Group type: EXPERIMENTAL
Intervention: Habit development
Number of subjects: 91
Study 30762916 — intervention group
Group type: EXPERIMENTAL
Intervention: Point-of-care ultrasound (POCUS)
Number of subjects: 217
Study 30762916 — intervention group
Group type: EXPERIMENTAL
Intervention: Expert review of POCUS images
Number of subjects: 217
Study 30762916 — intervention group
Group type: EXPERIMENTAL
Intervention: POCUS parameters for small-bowel dilation ≥ 25 mm
Number of subjects: 217
Study 30762916 — intervention group
Group type: EXPERIMENTAL
Intervention: POCUS parameters for abnormal peristalsis
Number of subjects: 217
Study 30762916 — intervention group
Group type: EXPERIMENTAL
Intervention: POCUS parameters for transition point
Number of subjects: 217
Study 30762916 — intervention group
Group type: EXPERIMENTAL
Intervention: Expert review parameters for transition point
Number of subjects: 217
Study 30762916 — intervention group
Group type: EXPERIMENTAL
Intervention: POCUS parameters for intraperitoneal free fluid
Number of subjects: 217
Study 30762916 — intervention group
Group type: EXPERIMENTAL
Intervention: Expert review parameters for intraperitoneal free fluid
Number of subjects: 217
Study 30762916 — intervention group
Group type: EXPERIMENTAL
Intervention: POCUS parameters for bowel wall edema
Number of subjects: 217
Study 30762916 — intervention group
Group type: EXPERIMENTAL
Intervention: Expert review parameters for bowel wall edema
Number of subjects: 217
Study 30763338 — intervention group
Group type: EXPERIMENTAL
Intervention: Epirubicin and cyclophosphamide followed by nab-paclitaxel (with trastuzumab if HER2-amplified)
Number of subjects: 51
Study 30764641 — intervention group
Group type: EXPERIMENTAL
Intervention: 320-slice CTA
Number of subjects: 381
Study 30764644 — intervention group
Group type: EXPERIMENTAL
Intervention: Charcoal-heated hookah smoking
Number of subjects: 30
Study 30764644 — intervention group
Group type: COMPARATOR
Intervention: Electrically heated hookah smoking
Number of subjects: 30
Study 30764644 — intervention group
Group type: COMPARATOR
Intervention: Cigarette smoking
Number of subjects: 30
Study 30764644 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% CO gas mixture inhalation
Number of subjects: 30
Study 30764654 — intervention group
Group type: COMPARATOR
Intervention: SDM tool with coaching
Number of subjects: 581
Study 30764654 — intervention group
Group type: COMPARATOR
Intervention: SDM tool without coaching
Number of subjects: 581
Study 30764654 — intervention group
Group type: COMPARATOR
Intervention: SDM tool (with or without coaching)
Number of subjects: 581
Study 30764687 — intervention group
Group type: EXPERIMENTAL
Intervention: Female sex
Number of subjects: 2596
Study 30764687 — intervention group
Group type: COMPARATOR
Intervention: Delay to hospital presentation of ≤120 minutes
Number of subjects: 2596
Study 30764687 — intervention group
Group type: COMPARATOR
Intervention: Suboptimal post-PCI TIMI flow grade
Number of subjects: 2596
Study 30764729 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-month individualized, tailored PA counseling (face-to-face counseling and follow-up e-mail and telephone contacts)
Number of subjects: 300
Study 30764729 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-month individualized, tailored PA counseling
Number of subjects: 300
Study 30764729 — intervention group
Group type: EXPERIMENTAL
Intervention: Step-based PA behavior change
Number of subjects: 300
Study 30764729 — intervention group
Group type: COMPARATOR
Intervention: Reference group (no PA counseling)
Number of subjects: 300
Study 30764793 — intervention group
Group type: EXPERIMENTAL
Intervention: HPP patients (regardless of prior or current treatment)
Number of subjects: 269
Study 30764800 — intervention group
Group type: EXPERIMENTAL
Intervention: High indoxyl sulfate (IS) group (IS level ≥ 2.74 μg/ml)
Number of subjects: 94
Study 30764800 — intervention group
Group type: EXPERIMENTAL
Intervention: Low indoxyl sulfate (IS) group (IS level < 2.74 μg/ml)
Number of subjects: 94
Study 30764800 — intervention group
Group type: EXPERIMENTAL
Intervention: Indoxyl sulfate level ≥ 2.74 μg/ml
Number of subjects: 94
Study 30764800 — intervention group
Group type: EXPERIMENTAL
Intervention: Kaplan-Meier analysis
Number of subjects: 94
Study 30765035 — intervention group
Group type: EXPERIMENTAL
Intervention: Low coronary flow reserve
Number of subjects: 224
Study 30765035 — intervention group
Group type: EXPERIMENTAL
Intervention: Low coronary blood flow
Number of subjects: 224
Study 30765035 — intervention group
Group type: EXPERIMENTAL
Intervention: Decrease in cross-sectional area in response to IC acetylcholine
Number of subjects: 224
Study 30765035 — intervention group
Group type: COMPARATOR
Intervention: Epicardial IC-nitroglycerin dilation
Number of subjects: 224
Study 30765123 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct-acting antivirals
Number of subjects: 9895
Study 30765123 — intervention group
Group type: COMPARATOR
Intervention: Untreated
Number of subjects: 9895
Study 30765258 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab (200 mg every 3 weeks) plus trastuzumab (6 mg/kg) in phase 2
Number of subjects: 58
Study 30765258 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab (2 mg/kg and 10 mg/kg every 3 weeks) plus trastuzumab (6 mg/kg) in phase 1b
Number of subjects: 58
Study 30765258 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment-related adverse events
Number of subjects: 58
Study 30765258 — intervention group
Group type: EXPERIMENTAL
Intervention: Serious adverse events
Number of subjects: 58
Study 30765258 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment-related death
Number of subjects: 58
Study 30766449 — intervention group
Group type: EXPERIMENTAL
Intervention: Cochlear implantation
Number of subjects: 150
Study 30766449 — intervention group
Group type: COMPARATOR
Intervention: CROS hearing aids
Number of subjects: 150
Study 30766449 — intervention group
Group type: COMPARATOR
Intervention: Bone conduction (BC) device
Number of subjects: 150
Study 30766449 — intervention group
Group type: EXPERIMENTAL
Intervention: Cochlear implantation (delayed insertion)
Number of subjects: 150
Study 30766449 — intervention group
Group type: EXPERIMENTAL
Intervention: Cochlear implantation (immediate insertion)
Number of subjects: 150
Study 30766492 — intervention group
Group type: EXPERIMENTAL
Intervention: Vortioxetine, dosage and duration not available
Number of subjects: 0
Study 30766508 — intervention group
Group type: EXPERIMENTAL
Intervention: Robot-Assisted Upper Limb Training
Number of subjects: 0
Study 30766508 — intervention group
Group type: COMPARATOR
Intervention: Botulinum Toxin
Number of subjects: 0
Study 30766686 — intervention group
Group type: EXPERIMENTAL
Intervention: GEM (technology-assisted health coaching intervention)
Number of subjects: 0
Study 30766686 — intervention group
Group type: COMPARATOR
Intervention: Enhanced Usual Care (EUC)
Number of subjects: 0
Study 30766706 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher initial AMH concentrations
Number of subjects: 0
Study 30766706 — intervention group
Group type: EXPERIMENTAL
Intervention: Women in the 3rd quartile of AMH
Number of subjects: 0
Study 30766706 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher AMH
Number of subjects: 0
Study 30767112 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipragliflozin
Number of subjects: 11051
Study 30767326 — intervention group
Group type: EXPERIMENTAL
Intervention: Probable cases (PTSD) identified with a threshold probability of 0.7
Number of subjects: 16000
Study 30767326 — intervention group
Group type: COMPARATOR
Intervention: Probable controls (without PTSD) identified with a threshold probability of 0.7
Number of subjects: 16000
Study 30767353 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin
Number of subjects: 0
Study 30767431 — intervention group
Group type: EXPERIMENTAL
Intervention: cfDNA in plasma
Number of subjects: 50
Study 30767431 — intervention group
Group type: EXPERIMENTAL
Intervention: cfDNA in sputum
Number of subjects: 50
Study 30767431 — intervention group
Group type: EXPERIMENTAL
Intervention: cfDNA in urine
Number of subjects: 50
Study 30767431 — intervention group
Group type: EXPERIMENTAL
Intervention: cfDNA from combination of plasma, sputum, and urine
Number of subjects: 50
Study 30767431 — intervention group
Group type: EXPERIMENTAL
Intervention: cfDNA in sputum (smoking history)
Number of subjects: 50
Study 30767431 — intervention group
Group type: EXPERIMENTAL
Intervention: cfDNA in sputum (no smoking history)
Number of subjects: 50
Study 30767431 — intervention group
Group type: EXPERIMENTAL
Intervention: cfDNA in plasma (smoking patients)
Number of subjects: 50
Study 30767587 — intervention group
Group type: EXPERIMENTAL
Intervention: Ridinilazole
Number of subjects: 0
Study 30767587 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 0
Study 30767706 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoniazid (dosage not specified)
Number of subjects: 172
Study 30767706 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifampicin (dosage not specified)
Number of subjects: 172
Study 30767902 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based training program and practice implementation toolkit with face-to-face training
Number of subjects: 100
Study 30767902 — intervention group
Group type: COMPARATOR
Intervention: Internet-based training program and practice implementation toolkit without face-to-face training
Number of subjects: 100
Study 30767903 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-accessible game intervention
Number of subjects: 240
Study 30767903 — intervention group
Group type: COMPARATOR
Intervention: Control condition (list of SGMY-inclusive resources)
Number of subjects: 240